8 research outputs found
Direct Plasma Metabolite Analysis of Positron Emission Tomography Radioligands by Micellar Liquid Chromatography with Radiometric Detection
Determination of radio-metabolites in plasma samples
taken during a positron emission tomography (PET) study is an important
component in the pharmacokinetic evaluation of PET radioligands. We
have developed and validated a new analytical procedure for the plasma
metabolite analysis of PET radioligands based on micellar liquid chromatography
using an anionic surfactant mobile phase. Chromatographic separation
was performed on an octadecyl semipreparative column (10 mm I.D. ×
160 mm, 10 μm) using 100 mM sodium dodecyl sulfate (SDS) and
1-butanol in 10 mM sodium-phosphate (pH 7.2) at a flow rate of 5 mL/min.
The samples taken from monkey or human plasma during PET measurements
were directly injected into a liquid chromatographic (LC) system coupled
to an online radiometric detector under micellar conditions using
1–2% (v/v) 1-butanol mobile phase to remove plasma proteins
and concentrate the analytes at the column head. At 2 min, mobile
phase was changed to elute and separate PET radioligand and its radiometabolites
with high peak capacity under high submicellar conditions (10–25%
1-butanol). This procedure allowed direct plasma injection (up to
2 mL) into the LC column without any pretreatment with a short analysis-time
of 8–10 min. Satisfactory reproducibility, linearity, sensitivity,
accuracy and recovery were obtained in the validation study. The developed
method was successfully applied to study the metabolism for diverse
groups of PET radioligands and provided reliable determination of
PET radioligands in human and monkey plasma. This method is advantageous
in terms of simplifying and shortening the processes required to analyze
short-lived radioligands as well as in providing a more accurate estimation
of the metabolite corrected input function, especially for the radioligands
with lower recoveries or degradation potential during the deproteination
process in a conventional procedure
Direct Plasma Metabolite Analysis of Positron Emission Tomography Radioligands by Micellar Liquid Chromatography with Radiometric Detection
Determination of radio-metabolites in plasma samples
taken during a positron emission tomography (PET) study is an important
component in the pharmacokinetic evaluation of PET radioligands. We
have developed and validated a new analytical procedure for the plasma
metabolite analysis of PET radioligands based on micellar liquid chromatography
using an anionic surfactant mobile phase. Chromatographic separation
was performed on an octadecyl semipreparative column (10 mm I.D. ×
160 mm, 10 μm) using 100 mM sodium dodecyl sulfate (SDS) and
1-butanol in 10 mM sodium-phosphate (pH 7.2) at a flow rate of 5 mL/min.
The samples taken from monkey or human plasma during PET measurements
were directly injected into a liquid chromatographic (LC) system coupled
to an online radiometric detector under micellar conditions using
1–2% (v/v) 1-butanol mobile phase to remove plasma proteins
and concentrate the analytes at the column head. At 2 min, mobile
phase was changed to elute and separate PET radioligand and its radiometabolites
with high peak capacity under high submicellar conditions (10–25%
1-butanol). This procedure allowed direct plasma injection (up to
2 mL) into the LC column without any pretreatment with a short analysis-time
of 8–10 min. Satisfactory reproducibility, linearity, sensitivity,
accuracy and recovery were obtained in the validation study. The developed
method was successfully applied to study the metabolism for diverse
groups of PET radioligands and provided reliable determination of
PET radioligands in human and monkey plasma. This method is advantageous
in terms of simplifying and shortening the processes required to analyze
short-lived radioligands as well as in providing a more accurate estimation
of the metabolite corrected input function, especially for the radioligands
with lower recoveries or degradation potential during the deproteination
process in a conventional procedure
Direct Plasma Metabolite Analysis of Positron Emission Tomography Radioligands by Micellar Liquid Chromatography with Radiometric Detection
Determination of radio-metabolites in plasma samples
taken during a positron emission tomography (PET) study is an important
component in the pharmacokinetic evaluation of PET radioligands. We
have developed and validated a new analytical procedure for the plasma
metabolite analysis of PET radioligands based on micellar liquid chromatography
using an anionic surfactant mobile phase. Chromatographic separation
was performed on an octadecyl semipreparative column (10 mm I.D. ×
160 mm, 10 μm) using 100 mM sodium dodecyl sulfate (SDS) and
1-butanol in 10 mM sodium-phosphate (pH 7.2) at a flow rate of 5 mL/min.
The samples taken from monkey or human plasma during PET measurements
were directly injected into a liquid chromatographic (LC) system coupled
to an online radiometric detector under micellar conditions using
1–2% (v/v) 1-butanol mobile phase to remove plasma proteins
and concentrate the analytes at the column head. At 2 min, mobile
phase was changed to elute and separate PET radioligand and its radiometabolites
with high peak capacity under high submicellar conditions (10–25%
1-butanol). This procedure allowed direct plasma injection (up to
2 mL) into the LC column without any pretreatment with a short analysis-time
of 8–10 min. Satisfactory reproducibility, linearity, sensitivity,
accuracy and recovery were obtained in the validation study. The developed
method was successfully applied to study the metabolism for diverse
groups of PET radioligands and provided reliable determination of
PET radioligands in human and monkey plasma. This method is advantageous
in terms of simplifying and shortening the processes required to analyze
short-lived radioligands as well as in providing a more accurate estimation
of the metabolite corrected input function, especially for the radioligands
with lower recoveries or degradation potential during the deproteination
process in a conventional procedure
Discovery of a Novel Muscarinic Receptor PET Radioligand with Rapid Kinetics in the Monkey Brain
Positron emission
tomography (PET), together with a suitable radioligand,
is one of the more prominent methods for measuring changes in synaptic
neurotransmitter concentrations in vivo. The radioligand of choice
for such measurements on the cholinergic system is the muscarinic
receptor antagonist <i>N</i>-[1-<sup>11</sup>C]propyl-3-piperidyl
benzilate (PPB). In an effort to overcome the shortcomings with the
technically cumbersome synthesis of [<sup>11</sup>C]PPB, we designed
and synthesized four structurally related analogues of PPB, of which
(<i>S</i>,<i>R</i>)-1-methylpiperidin-3-yl)2-cyclopentyl-2-hydroxy-2-phenylacetate
(<b>1</b>) was found to bind muscarinic receptors with similar
affinity as PPB (3.5 vs 7.9 nM, respectively). (<i>S</i>,<i>R</i>)<b>-1</b> was radiolabeled via <i>N</i>-<sup>11</sup>C-methylation at high radiochemical purity
(>99%) and high specific radioactivity (>130 GBq/μmol).
In vitro
studies by autoradiography on human brain tissue and in vivo studies
by PET in nonhuman primates demonstrated excellent signal-to-noise
ratios and a kinetic profile in brain comparable to that of [<sup>11</sup>C]PBB. (<i>S</i>,<i>R</i>)-[<sup>11</sup>C]<b>1</b> is a promising candidate for measuring changes in
endogenous acetylcholine concentrations
Development of [<i>Carbonyl</i>-<sup>11</sup>C]AZ13198083, a Novel Histamine Type‑3 Receptor Radioligand with Favorable Kinetics
The
histamine subtype-3 receptor (H<sub>3</sub>R) is implicated
in a range of central nervous system disorders, and several radioligands
have been developed for H<sub>3</sub>R positron emission tomography
imaging. However, a limitation of currently used PET radioligands
for H<sub>3</sub>R is the slow binding kinetics in high density brain
regions. To address this, we herein report the development of three
novel candidate H<sub>3</sub>R radioligands, namely, [<i>carbonyl</i>-<sup>11</sup>C]AZ13153556 ([<i>carbonyl</i>-<sup>11</sup>C]<b>4</b>), [<i>carbonyl</i>-<sup>11</sup>C]AZD5213([<i>carbonyl</i>-<sup>11</sup>C]<b>5</b>), and [<i>carbonyl</i>-<sup>11</sup>C]AZ13198083 ([<i>carbonyl</i>-<sup>11</sup>C]<b>6</b>), and their subsequent preclinical evaluation in
nonhuman primates (NHP). Radioligands [<i>carbonyl</i>-<sup>11</sup>C]<b>4</b>–<b>6</b> were produced and
isolated in high radioactivity (>1000 MBq), radiochemical purity
(>99%),
and moderate molar activity (19–28 GBq/μmol at time of
injection) using a palladium-mediated <sup>11</sup>C-aminocarbonylation
protocol. All three radioligands showed high brain permeability as
well as a regional brain radioactivity distribution in accordance
with H<sub>3</sub>R expression (striatum > cortex > cerebellum).
[<i>Carbonyl</i>-<sup>11</sup>C]<b>6</b> displayed
the most
favorable in vivo kinetics and brain uptake, with an early peak in
the striatal time–activity curve followed by a progressive
washout from the brain. The specificity and on-target kinetics of
[<i>carbonyl</i>-<sup>11</sup>C]<b>6</b> were next
investigated in pretreatment and displacement studies. After pretreatment
or displacement with <b>5</b> (0.1 mg/kg), a uniformly low distribution
of radioactivity across the NHP brain was observed. Collectively,
this work demonstrates that [<i>carbonyl</i>-<sup>11</sup>C]<b>6</b> is a promising candidate for H<sub>3</sub>R imaging
in human subjects
Microsome Mediated in Vitro Metabolism: A Convenient Method for the Preparation of the PET Radioligand Metabolite [<sup>18</sup>F]FE-PE2I-OH for Translational Dopamine Transporter Imaging
Undesired
radiometabolites can be detrimental to the development
of positron emission tomography (PET) radioligands. Methods for quantifying
radioligand metabolites in brain tissue include ex vivo studies in
small animals or labeling and imaging of the radiometabolite(s) of
interest. The latter is a time- and resource-demanding process, which
often includes multistep organic synthesis. We hypothesized that this
process could be replaced by making use of liver microsomes, an in
vitro system that mimics metabolism. In this study, rat liver microsomes
were used to prepare radiometabolites of the dopamine transporter
radioligand [18F]FE-PE2I for in vitro imaging using autoradiography
and in vivo imaging using PET in rats and nonhuman primates. The primary
investigated hydroxy-metabolite [18F]FE-PE2I-OH ([18F]2) was obtained in a 2% radiochemical yield
and >99% radiochemical purity. In vitro and in vivo imaging demonstrated
that [18F]2 readily crossed the blood–brain
barrier and bound specifically and reversibly to the dopamine transporter.
In conclusions, the current study demonstrates the potential of liver
microsomes in the production of radiometabolites for translational
imaging studies and radioligand discovery
Development of [<i>Carbonyl</i>-<sup>11</sup>C]AZ13198083, a Novel Histamine Type‑3 Receptor Radioligand with Favorable Kinetics
The
histamine subtype-3 receptor (H<sub>3</sub>R) is implicated
in a range of central nervous system disorders, and several radioligands
have been developed for H<sub>3</sub>R positron emission tomography
imaging. However, a limitation of currently used PET radioligands
for H<sub>3</sub>R is the slow binding kinetics in high density brain
regions. To address this, we herein report the development of three
novel candidate H<sub>3</sub>R radioligands, namely, [<i>carbonyl</i>-<sup>11</sup>C]AZ13153556 ([<i>carbonyl</i>-<sup>11</sup>C]<b>4</b>), [<i>carbonyl</i>-<sup>11</sup>C]AZD5213([<i>carbonyl</i>-<sup>11</sup>C]<b>5</b>), and [<i>carbonyl</i>-<sup>11</sup>C]AZ13198083 ([<i>carbonyl</i>-<sup>11</sup>C]<b>6</b>), and their subsequent preclinical evaluation in
nonhuman primates (NHP). Radioligands [<i>carbonyl</i>-<sup>11</sup>C]<b>4</b>–<b>6</b> were produced and
isolated in high radioactivity (>1000 MBq), radiochemical purity
(>99%),
and moderate molar activity (19–28 GBq/μmol at time of
injection) using a palladium-mediated <sup>11</sup>C-aminocarbonylation
protocol. All three radioligands showed high brain permeability as
well as a regional brain radioactivity distribution in accordance
with H<sub>3</sub>R expression (striatum > cortex > cerebellum).
[<i>Carbonyl</i>-<sup>11</sup>C]<b>6</b> displayed
the most
favorable in vivo kinetics and brain uptake, with an early peak in
the striatal time–activity curve followed by a progressive
washout from the brain. The specificity and on-target kinetics of
[<i>carbonyl</i>-<sup>11</sup>C]<b>6</b> were next
investigated in pretreatment and displacement studies. After pretreatment
or displacement with <b>5</b> (0.1 mg/kg), a uniformly low distribution
of radioactivity across the NHP brain was observed. Collectively,
this work demonstrates that [<i>carbonyl</i>-<sup>11</sup>C]<b>6</b> is a promising candidate for H<sub>3</sub>R imaging
in human subjects
Discovery and Preclinical Validation of [<sup>11</sup>C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor
The histamine type 3 receptor (H<sub>3</sub>) is a G protein-coupled
receptor implicated in several disorders of the central nervous system.
Herein, we describe the radiolabeling and preclinical evaluation of
a candidate radioligand for the H<sub>3</sub> receptor, 4-(1<i>S</i>,2<i>S</i>)-2-(4-cyclobutylpiperazine-1-carbonyl)cyclopropyl]-<i>N</i>-methyl-benzamide (<b>5</b>), and its comparison
with one of the frontrunner radioligands for H<sub>3</sub> imaging,
namely, GSK189254 (<b>1</b>). Compounds <b>1</b> and <b>5</b> were radiolabeled with tritium and carbon-11 for in vitro
and in vivo imaging experiments. The in vitro binding of [<sup>3</sup>H]<b>1</b> and [<sup>3</sup>H]<b>5</b> was examined by
(i) saturation binding to rat and nonhuman primate brain tissue homogenate
and (ii) in vitro autoradiography on tissue sections from rat, guinea
pig, and human brain. The in vivo binding of [<sup>11</sup>C]<b>1</b> and [<sup>11</sup>C]<b>5</b> was examined by PET imaging
in mice and nonhuman primates. <i>B</i><sub>max</sub> values
obtained from Scatchard analysis of [<sup>3</sup>H]<b>1</b> and
[<sup>3</sup>H]<b>5</b> binding were in good agreement. Autoradiography
with [<sup>3</sup>H]<b>5</b> on rat, guinea pig, and human brain
slices showed specific binding in regions known to be enhanced in
H<sub>3</sub> receptors, a high degree of colocalization with [<sup>3</sup>H]<b>1</b>, and virtually negligible nonspecific binding
in tissue. PET measurements in mice and nonhuman primates demonstrated
that [<sup>11</sup>C]<b>5</b> binds specifically and reversibly
to H<sub>3</sub> receptors in vivo with low nonspecific binding in
brain tissue. Whereas [<sup>11</sup>C]<b>1</b> showed similar
binding characteristics in vivo, the binding kinetics appeared faster
for [<sup>11</sup>C]<b>5</b> than for [<sup>11</sup>C]<b>1</b>. Conclusions: [<sup>11</sup>C]<b>5</b> has suitable
properties for quantification of H<sub>3</sub> receptors in nonhuman
primate brain and has the potential to offer improved binding kinetics
in man compared to [<sup>11</sup>C]<b>1</b>